Analysis of prediction improvement with established prediction tools through additional information on risk-related N-glycans
| . | RIcases (95% CI) . | RInoncases (95% CI) . | NRI (95% CI) . |
|---|---|---|---|
| Type 2 diabetes risk | |||
| GDRS vs. GDRS+GST2D | 0.42 (0.37–0.46) | 0.20 (0.19–0.22) | 0.62 (0.53–0.71) |
| Glucmarkers vs. GDRS+GST2D | 0.64 (0.61–0.68) | 0.22 (0.21–0.23) | 0.87 (0.79–0.94) |
| CVD risk men | |||
| AHA score vs. AHA score+GSCVD | 0.01 (−0.03 to 0.04) | 0.31 (0.30–0.32) | 0.31 (0.24–0.39) |
| CVD risk women | |||
| AHA score vs. AHA score+GP5 | 0.50 (0.46–0.54) | 0.08 (0.07–0.09) | 0.58 (0.49–0.67) |
| . | RIcases (95% CI) . | RInoncases (95% CI) . | NRI (95% CI) . |
|---|---|---|---|
| Type 2 diabetes risk | |||
| GDRS vs. GDRS+GST2D | 0.42 (0.37–0.46) | 0.20 (0.19–0.22) | 0.62 (0.53–0.71) |
| Glucmarkers vs. GDRS+GST2D | 0.64 (0.61–0.68) | 0.22 (0.21–0.23) | 0.87 (0.79–0.94) |
| CVD risk men | |||
| AHA score vs. AHA score+GSCVD | 0.01 (−0.03 to 0.04) | 0.31 (0.30–0.32) | 0.31 (0.24–0.39) |
| CVD risk women | |||
| AHA score vs. AHA score+GP5 | 0.50 (0.46–0.54) | 0.08 (0.07–0.09) | 0.58 (0.49–0.67) |